BFB-101 (AAV9-CBh-AP4B1)

Gene therapy

BFB-101 (AAV9-CBh-AP4B1) is one of 3 biologic programs targeting Hereditary Spastic Paraplegia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary Spastic ParaplegiaActive, not recruiting

Hereditary Spastic ParaplegiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Hereditary Spastic Paraplegia

#DrugCompanyPhaseTrials

Wellcovorin

EEastern Cooperative Oncology Group

Phase 1

—2

Ampyra

MMerz Pharmaceuticals GmbH

Preclinical

1 3

BFB-101 (AAV9-CBh-AP4B1)

BBlackfinBio Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 1/2Not yet recruiting

Hereditary Spastic Paraplegia

NCT06948019

Clinical

Trials by Indication[1]

Hereditary Spastic Paraplegia1 trial

Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)

Not yet recruiting·BBlackfinBio Ltd·Phase 1/2·NCT06948019·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BFB-101 (AAV9-CBh-AP4B1). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BFB-101 (AAV9-CBh-AP4B1) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BFB-101 (AAV9-CBh-AP4B1). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BlackfinBio Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Company: BBlackfinBio Ltd

BFB-101 (AAV9-CBh-AP4B1)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Hereditary Spastic Paraplegia1 trial

References

Drug Info

Quick Facts

Related News